EARLY BREAST CANCER

This large Phase 3 study tests a new drug, giredestrant, against standard hormone therapies in about 4,170 people with early-stage, hormone-sensitive breast cancer. The goal is to see if giredestrant is better at preventing the cancer from returning after initial treatment. Parti…

This study tests whether a shorter, more focused radiation treatment (accelerated partial breast irradiation) after breast-conserving surgery can effectively control cancer in the breast and nearby lymph nodes for people with early-stage breast cancer. About 537 participants with…

This study tests if a combination of ribociclib (a targeted pill) and hormone therapy works better than standard chemotherapy for women with a common type of early breast cancer (HR+/HER2-). About 1,684 women with intermediate-risk disease are taking part. The goal is to see whic…

This phase 2 trial is testing whether a combination of targeted cancer drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer without traditional chemotherapy. About 393 patients will receive these drugs as a subcutaneous injection, wit…

This phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to re…

This study tests whether a combination of two pills (letrozole and abemaciclib) works as well as standard chemotherapy before surgery in women with a common type of early breast cancer (HR-positive, HER2-negative) that is at high or intermediate risk of coming back. About 200 wom…

This phase II trial is testing a less intense chemotherapy regimen for people with early-stage HER2-positive breast cancer. The experimental treatment combines paclitaxel with two targeted drugs (trastuzumab and pertuzumab), skipping the harsher anthracycline drugs. Researchers w…

This study looks at whether young women with early-stage, hormone-sensitive breast cancer can temporarily stop their hormone therapy to try to get pregnant without raising their risk of cancer coming back. It involves 518 women aged 18 to 42 who have already been on hormone thera…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapy can lower the chance of breast cancer returning in postmenopausal women with a high-risk type. About 123 participants will receive either hormone therapy alone or with abemaciclib for up to 2…

This phase 3 trial studies whether adding the drug abemaciclib (Verzenios) to standard hormone therapy helps prevent breast cancer from coming back in 1,260 women with high-risk, HR+/HER2- early breast cancer. Participants have already completed initial treatments like surgery or…

This study was designed to test whether a biosimilar version of pertuzumab (EG1206A) works as well as the original drug (Perjeta) in people with HER2-positive, hormone receptor-negative early breast cancer. Participants would have received either the biosimilar or the original dr…

This study is testing an artificial intelligence (AI) tool that analyzes digitized images of tumor tissue from 2,200 women with ER-positive, HER2-negative early breast cancer. The AI aims to predict the risk of cancer spreading to distant parts of the body. Researchers will compa…

This phase 3 trial tests whether mecobalamin (a form of vitamin B12) can prevent severe hand-foot syndrome in early breast cancer patients taking capecitabine. About 234 women will receive either mecobalamin or a placebo. The goal is to see if the vitamin reduces painful skin rea…

This study is testing commercially available antibodies to see if they can identify breast cancer markers in blood samples. Researchers will collect blood from 84 people, including breast cancer patients and healthy volunteers. The goal is to improve detection of circulating tumo…